pharmaphorum11 小时
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
The Pharma Letter21 小时
Gilead and Merck tout first weekly oral HIV treatment
US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...
来自MSN1 天
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV ...
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Business Wire1 天
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
manilatimes5 天
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery ...
ElevateBio aims to be the dominant engine inside the world's greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on ...